STACIE RAMSEY: Open Payments
NPI 1336405455 · GULFPORT, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$795 in 42 payments from 15 companies in 2025. Trend: 2023 $1,323 · 2024 $612 · 2025 $795
Food & beverage: $795
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 11 | $229 |
| ABBVIE INC. | 11 | $198 |
| AstraZeneca Pharmaceuticals LP | 5 | $82 |
| Janssen Pharmaceuticals, Inc | 2 | $42 |
| GlaxoSmithKline, LLC. | 2 | $38 |
| Phathom Pharmaceuticals, Inc. | 2 | $32 |
| UCB, Inc. | 1 | $25 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $24 |
| Abbott Laboratories | 1 | $21 |
| Amgen Inc. | 1 | $20 |
Products named: Ozempic, VRAYLAR, AIRSUPRA, QULIPTA, UBRELVY, SPRAVATO, TRELEGY ELLIPTA, VOQUEZNA.
Industry payments across MS — which companies pay providers there.
